Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
New results suggest earlier treatment may increase the likelihood of long-term remission Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Xinhua Silk Road: Zhejiang's Yandangshan in E China expands partnerships with more int'l peers
- Cozy Up with Beef: Three Comfort Food Classics for Autumn Evenings
- CGTN: Warum die Welt das Treffen zwischen Xi und Trump aufmerksam verfolgt: Die Beziehungen zwischen China und den USA lenken, die Zukunft gestalten
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →